Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1CNS 1

Conditions

Glioblastoma 472Brain Neoplasms 306Glioma 257Neoplasms 122Astrocytoma 88Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 70Neuroblastoma 65Central Nervous System Neoplasms 61Melanoma 58Recurrence 46Lung Neoplasms 45Pancreatic Neoplasms 41Oligodendroglioma 37Ovarian Neoplasms 36Colorectal Neoplasms 36Neoplasm Metastasis 33Sarcoma 32Medulloblastoma 28Stomach Neoplasms 27Gliosarcoma 27Lymphoma 25Prostatic Neoplasms 24Head and Neck Neoplasms 24Neurofibromatosis 1 23Rhabdomyosarcoma 21Neurofibroma, Plexiform 19Esophageal Neoplasms 19Diffuse Intrinsic Pontine Glioma 19Cholangiocarcinoma 19

Interventions

spartalizumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hereditary leiomyomatosis and renal cell cancer × CNS × Clear all
NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Novartis

Phase 1 Terminated
40 enrolled
CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡